Exercise hormone halts Parkinson’s disease symptoms, study finds
[Sept 14, 2022: Vanessa Wasta, Johns Hopkins Medicine]
Parkinson’s disease, a neurologic condition that causes people to lose control over their muscles and movements, affects about 1 million people in the U.S. (CREDIT: Creative Commons)
Researchers from Johns Hopkins Medicine and the Dana Farber Cancer Institute in Boston have shown that a hormone secreted into the blood during endurance, or aerobic, exercise reduces levels of a protein linked to Parkinson’s disease and halts movement problems in mice.
Parkinson’s disease, a neurologic condition that causes people to lose control over their muscles and movements, affects about 1 million people in the U.S.
If confirmed in additional laboratory research and clinical trials, the researchers’ study in mice engineered to have Parkinson’s disease symptoms could pave the way for a Parkinson’s disease therapy based on the hormone irisin.
Results of the researchers’ tests appeared Aug. 31 in Proceedings of the National Academy of Sciences.
Johns Hopkins Medicine’s Ted Dawson, M.D., Ph.D., and Dana Farber’s Bruce Spiegelman, Ph.D., worked together to look into the link between the exercise molecule irisin and Parkinson’s disease.
For unknown reasons, endurance exercise has long been found to alleviate symptoms of Parkinson’s disease.
Dawson, whose research focuses on neurodegenerative diseases, including Parkinson’s disease, said one of the first clues to the link between exercise, Parkinson’s disease and irisin came from Spiegelman, whose first paper about irisin was published in 2012 in Nature and subsequently in other scientific journals, showing that a protein called an irisin peptide is released into the blood and increases with endurance exercise.
In the past decade, other laboratories have found that exercise elevates levels of irisin, and there is interest in looking into the connection between irisin and Alzheimer’s disease as well as Parkinson’s disease.
To test the effects of irisin on Parkinson’s disease, Dawson and Spiegelman’s teams began with a research model used by Dawson in which mouse brain cells are engineered to spread small, spindly fibers of alpha synuclein, a protein that regulates moods and movements related to the brain neurotransmitter dopamine.
When alpha synuclein proteins clump, those clusters kill dopamine-producing brain cells, a key trigger of Parkinson’s disease. Fibrous clumps of alpha synuclein are very similar, says Dawson, to what is found in the brains of people with Parkinson’s disease.
In the laboratory model, the researchers found that irisin prevented the accumulation of alpha synuclein clumps and its associated brain cell death.
Next, the research teams tested irisin’s effects on mice engineered to have Parkinson’s-like symptoms. They injected alpha synuclein into an area of the mouse brain, called the striatum, where dopamine-producing neurons extend.
Two weeks later, the researchers injected a viral vector, which increased blood levels of irisin, which can cross the blood-brain barrier, into the mice. Six months later, mice that received irisin had no muscle movement deficits, while those injected with a placebo showed deficits in grip strength and their ability to descend a pole.
Additional studies of brain cells among the mice given irisin showed that the exercise hormone lowered levels of Parkinson’s disease-related alpha synuclein between 50% and 80%. The research team demonstrated that irisin also speeds up the transport and degradation of alpha synuclein via fluid-filled sacs called lysosomes in brain cells.
Irisin protects neurons against α-syn PFF neurotoxicity. (A) Representative images of pS129-α-syn (green) in primary cortical neurons preincubated for 1 h followed by sustained treatment with indicated concentration of irisin, and further incubated with α-syn PFF (1 μg/mL) for 7 d. DAPI (blue) was used for nuclei staining. (Scale bar, 20 μm.) (B) Quantification of p-α-syn signals in (A) normalized with DAPI. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 3). (C) Representative immunoblots of pS129-α-syn and α-syn in the Triton X-100-soluble and insoluble fraction from primary cortical neurons preincubated for 1 h followed by sustained treatment with indicated concentration of irisin followed by incubation with α-syn PFF for 7 d. (D) Quantification of levels of pS129-α-syn and α-syn in the Triton X-100-insoluble fraction normalized to β-actin shown in (C). Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 4). (E) Cell death assay quantified from Hoechst and propidium iodide (PI) staining in primary cortical neurons treated for 1 h followed by sustained treatment with indicated concentration of irisin and further incubated with α-syn PFF (5 μg/mL) for 14 d. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 4). (F) Cell death assay quantified from Hoechst and propidium iodide (PI) staining in primary cortical neurons preincubated 1 h followed by sustained treatment with irisin (50 ng/mL) and further incubated with α-syn PFF (5 μg/mL) for 14 d as well as delayed treatment (1 d, 2 d, 4 d, and 7 d) after α-syn PFF treatment. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 4). *P < 0.05, **P < 0.005, ***P < 0.0005. (CREDIT: Johns Hopkins Medicine)
“If irisin’s utility pans out, we could envision it being developed into a gene or recombinant protein therapy,” says Dawson, referring to the widening field of drug development aimed at using cellular genetics to treat disease. Dawson is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases, professor of neurology and director of the Johns Hopkins Institute for Cell Engineering.
“Given that irisin is a naturally produced peptide hormone and seems to have evolved to cross the blood brain-barrier, we think it is worth continuing to evaluate irisin as a potential therapy for Parkinson’s and other forms of neurodegeneration” adds Spiegelman.
Irisin reduces the α-syn levels. (A) Schematic diagram of proteomic analysis. (B, C) Volcano plot of protein alterations. The proteins quantified from primary cortical neurons with or without preincubation of irisin (50 ng/mL) and further incubated with α-syn PFF (1 μg/mL) for (B) one or (C) 4 d were analyzed for differentially expressed proteins in PFF- and irisin-treated cells. The cutoff used to select differentially expressed proteins was q-value < 0.05. (CREDIT: Johns Hopkins Medicine)
Dawson and Spiegelman have filed for patents on the use of irisin in Parkinson’s disease. Spiegelman has created a biotechnology company, Aevum Therapeutics Inc., based in Boston, to develop irisin into treatments for neurodegenerative disease.
Other scientists who contributed to the research include Tae-In Kam, Hyejin Park, Shih-Ching Chou, Yu Ree Choi, Devanik Biswas, Justin Wang, Yu Shin, Alexis Loder, Senthilkumar Karuppagounder and Valina Dawson at Johns Hopkins, and Jonathan Van Vranken, Melanie Mittenbuhler, Hyeonwoo Kim, Mu A and Christiane Wrann at Harvard Medical School.
The research was funded by the JPB Foundation, the Maryland Stem Cell Research Fund, the Mark Foundation for Cancer Research, the Damon Runyon Cancer Research Foundation and Deutsche Forschungsgemeinschaft.
For more science and technology stories check out our New Discoveries section at The Brighter Side of News.
Note: Materials provided above by the Johns Hopkins Medicine. Content may be edited for style and length.
Like these kind of feel good stories? Get the Brighter Side of News' newsletter.